Clinical Trials | June 13, 2026
Ryvu advances romaciclib program as FDA clears AML trial expansion
The regulatory decision follows promising results from RIVER-81
The regulatory decision follows promising results from RIVER-81
Approval is based on results from the phase 3 OASIS 4 clinical trial
MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms
Partnership will provide funding, incubation, mentorship, and industry exposure for ventures in healthcare, pharmaceuticals, biotechnology, medical technology, and agriculture
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
Two-year collaboration aims to strengthen primary healthcare systems, generate real-world evidence, and support responsible adoption of AI and digital health technologies across South-East Asia
The film tells the story of a 70-year-old woman from Kota, Rajasthan, whose persistent cough led to a diagnosis of advanced lung cancer
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
The union minister spoke at the 2nd Pharma Summit & Awards 2026 organised by ASSOCHAM in New Delhi
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
